Sharps Technology (STSS) Registration Filing summary

Company overview and business model

• Operates as a medical device and pharmaceutical packaging company, commercializing patented smart-safety syringe products with ultra-low waste and advanced safety features, and recently expanded into digital asset treasury management focused on Solana (SOL).

• Product lines include FDA-cleared safety syringes (Provensa and Securgard) and specialized copolymer technology for pre-fillable syringes.

• Adopted a treasury policy allocating a significant portion of the balance sheet to SOL, with staking and derivative strategies to generate yield and manage risk.

• Management oversees both medical device operations and digital asset treasury, with a strategic committee guiding the SOL strategy.

Financial performance and metrics

• Holds over 2,000,000 SOL as of the prospectus date, including staking rewards.

• Financial results and stock price are highly sensitive to SOL price volatility and regulatory developments.

Use of proceeds and capital allocation

• Proceeds from securities sales may be used for general corporate purposes, debt repayment, share repurchases, working capital, capital expenditures, acquisitions, and further implementation of the SOL Treasury Policy.

• Management retains broad discretion over timing and application of proceeds.